NASDAQ: SMMT · Biotechnology
Over the past week, Summit Therapeutics (SMMT) racked up about 23 mentions across Reddit, X and news, and the read is an Adanos Buy. The crowd averages 71% bullish but is sharply divided: News runs 100% bullish while Reddit sits at just 50%. Wall Street is more cautious, with 10 of 17 analysts rating SMMT a buy.
There is little buzz around SMMT this week and little agreement on direction, which is why it reads as a Buy.
Wall Street’s 59% buy share sits next to a crowd that ranges from Reddit at 50% to News at 100%. No other tracker puts the two side by side.
17 analysts have weighed in: a Buy consensus: 10 buy calls against 0 sell, with an average 12-month price target of $29.13.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits above the neutral line, momentum is mixed and the 3 sources disagree sharply, so the read is a Buy.
The crowd runs 12 points hotter than the 59% analyst buy share, retail is ahead of the Street here. The split is inside the crowd: News reads 100% bullish while Reddit sits at 50%, a 50-point spread that single-source trackers miss.
Over the 30-day window, Summit Therapeutics (SMMT) buzz held subdued around 37.2 while the price drifted up 25.4% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 6.5M shares. Over the last 7 trading days, SMMT gained 20.2%. Buzz activity in the recent week averaged 39.3 and was variable, swinging between 27.3 and 58.5. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 15 of the 20 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for SMMT and 2001+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live SMMT sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Sep 11, 2026.
| Adanos signal | Buy |
|---|---|
| Analyst consensus | Buy (10 / 7 / 0) |
| Crowd bullish (7d) | 71% |
| Avg price target | $29.13 |
| Most bullish source | News, 100% |
| Most bearish source | Reddit, 50% |
| Sentiment spread | 50 pts |
| Mentions (7d) | 23 |
| Market cap | $13.56B |
| P/E · Forward P/E | n/a · 3.7 |
| EPS · Beta | -$1.08 · -1.2 |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, Summit Therapeutics (SMMT) currently carries an Adanos buy signal with 93/100 conviction. The current cross-source average reads 71% bullish across 3 active sources. Those sources contribute 23 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around Summit Therapeutics (SMMT) is fairly quiet with 2 mentions over the last 7 days; the 30-day context spans 6 tracked subreddits. The 7-day tone is 50% bullish; 3-day activity momentum is stable, suggesting steady attention.
The crowd reads bullish on Summit Therapeutics (SMMT), averaging 71% bullish across 3 tracked sources over the last 7 days. The two ends of the range are News at 100% bullish and Reddit at 50%, a 50-point spread. On the professional side, 10 of 17 analysts rate SMMT a buy.
Of the 17 analysts covering Summit Therapeutics (SMMT), 10 rate it a buy, 7 a hold and 0 a sell, for a buy consensus. The average price target is $29.13. The crowd is the more bullish of the two, averaging 71%.
Summit Therapeutics (SMMT)'s cross-source average is bullish at 71% bullish. Source readings are split: 2 sources lean bullish and 1 source sits at 50% bullish. X reads 64% bullish, News reads 100% bullish and reddit coverage is the most negative at 50% bullish. The combined signal points to broad buy-side pressure with 93/100 conviction.
The cross-source average is bullish for Summit Therapeutics (SMMT) at 71% bullish. Source readings are split: 2 sources lean bullish and 1 source sits at 50% bullish. The most bearish reading is reddit at 50% bullish. 3-day activity momentum is falling on News, while x activity is rising. The buy signal carries 93/100 conviction.
X is the dominant discussion channel with 11 mentions (48% of total volume). News contributes 10 mentions and Reddit contributes 2 mentions. The cross-source average is bullish at 71% bullish, while x is the only source with rising 3-day activity. Source readings are split: 2 sources lean bullish and 1 source sits at 50% bullish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. SMMT's buy signal at 93/100 conviction reflects a bullish cross-source average at 71% bullish. Source readings are split: 2 sources lean bullish and 1 source sits at 50% bullish. It is a research shortcut, not financial advice.
The SMMT sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Buy signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key